Title:
AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/213308
Kind Code:
A1
Abstract:
The present invention provides an amide-substituted heterocyclic compound or an isomer, a solvate, a deuterated derivative or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, R4, Ⓐ, L, L1, X, X1, and Y1 are defined in the specification. In addition, the present invention further provides a medicament comprising the compound, the isomer, the solvate, the deuterated derivative, and the salt thereof as an active ingredient, and use thereof in preparing a medicament for treating a disease related to the Tyk2-mediated signaling pathway, such as an autoimmune disease and a cancer. Formula (I)
Inventors:
LI SHUXIN (CN)
Application Number:
PCT/CN2023/092333
Publication Date:
November 09, 2023
Filing Date:
May 05, 2023
Export Citation:
Assignee:
SUZHOU LONGBOTAI PHARMACEUTICALS CO LTD (CN)
International Classes:
A61K31/50; C07D213/82; A61K31/501; A61P29/00; A61P37/00; C07D401/12; C07D401/14; C07D403/12; C07D403/14; C07D405/12; C07D413/12; C07D413/14; C07D417/12; C07D417/14
Domestic Patent References:
| WO2021170046A1 | 2021-09-02 | |||
| WO2020156311A1 | 2020-08-06 |
Foreign References:
| CN113227071A | 2021-08-06 | |||
| CN106660960A | 2017-05-10 | |||
| CN111484480A | 2020-08-04 | |||
| CN111909140A | 2020-11-10 | |||
| CN113365982A | 2021-09-07 |
Other References:
WROBLESKI, S.T. ET AL.: "Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 20, 18 July 2019 (2019-07-18), XP055629848, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b00444
Attorney, Agent or Firm:
JJS INTELLECTUAL PROPERTY AGENCY LTD. (CN)
Download PDF: